Stockholder Alert: Robbins LLP Informs Investors that a Shareholder Has Filed a Class Action Against Biogen Inc. (BIIB)
May 24, 2024 20:18 ET
|
Robbins LLP
Robbins LLP is Investigating Allegations that Biogen Inc. (BIIB) Misled Investors Regarding its Financial Prospects
BIOGEN INC. (NASDAQ: BIIB) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Biogen Inc.
May 24, 2024 12:30 ET
|
Bernstein Liebhard LLP
BIOGEN INC. (NASDAQ: BIIB) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Biogen Inc.
BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
May 23, 2024 18:25 ET
|
Bronstein, Gewirtz & Grossman, LLC
NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been...
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Biogen Inc. with Losses to Contact the Firm
May 23, 2024 15:48 ET
|
Schall Law
The Schall Law Firm Encourages Investors in Biogen Inc. with Losses to Contact the Firm
Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Biogen, Inc. (BIIB)
May 23, 2024 12:36 ET
|
Gainey McKenna & Egleston
NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the District of...
BIIB INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead the Biogen Class Action Lawsuit
May 22, 2024 19:50 ET
|
Robbins Geller Rudman & Dowd LLP
SAN DIEGO, May 22, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that the Biogen class action lawsuit seeks to represent purchasers or acquirers of Biogen Inc. (NASDAQ:...
Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences
May 22, 2024 07:30 ET
|
Biogen Inc.
Transaction to include felzartamab, a potential first-in-class therapeutic candidate with promise as a pipeline-in-a-product across a range of immune-mediated diseasesFelzartamab is an investigational...
Multiple Sclerosis Drugs Market Outlook 2024-2028, 2033 - A $48 Billion Global Opportunity Dominated by Biogen, Novartis, Roche, Bayer HealthCare, and Pfizer
May 16, 2024 08:00 ET
|
Research and Markets
Dublin, May 16, 2024 (GLOBE NEWSWIRE) -- The "Multiple Sclerosis Drugs Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.The global multiple sclerosis drugs...
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
May 16, 2024 07:30 ET
|
Biogen Inc.
Development of BIIB105, an investigational antisense oligonucleotide for amyotrophic lateral sclerosis (ALS), will be discontinued based on data from the Phase 1/2 ALSpire studyBiogen and Ionis...
Oligonucleotide Synthesis Market is Expected to Reach $19.7 billion | MarketsandMarkets™
May 15, 2024 08:30 ET
|
MarketsandMarkets Research Pvt. Ltd.
Chicago, May 15, 2024 (GLOBE NEWSWIRE) -- Oligonucleotide Synthesis market in terms of revenue was estimated to be worth $8.8 billion in 2024 and is poised to reach $19.7 billion by 2029, growing at...